問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
吳錫金
下載
2025-04-01 - 2027-12-31
Condition/Disease
Test Drug
Participate Sites4Sites
Recruiting4Sites
2016-11-01 - 2022-10-28
metastatic hormone-sensitive prostate cancer
BAY 1841788/ODM-201(Darlutamide)
Participate Sites8Sites
Recruiting6Sites
2021-11-01 - 2022-08-29
Participate Sites6Sites
2021-06-01 - 2022-05-30
2020-04-01 - 2024-01-10
Metastatic Castration-resistant Prostate Cancer
OPDIVO (nivolumab) Injection 10mg/mL
全部
